Supportive Therapy and Toxicity
作者： Penelope Brock , Gill Levitt
DOI: 10.1007/978-3-642-14504-9_15
关键词: Hepatoblastoma 、 Chemotherapy 、 Doxorubicin 、 Medicine 、 Internal medicine 、 Cisplatin 、 Anthracycline 、 Oncology 、 Supportive psychotherapy 、 Hepatocellular carcinoma 、 Cumulative dose
摘要: The treatment of primary liver cancers in children requires chemotherapy addition to surgery for cure. most effective chemotherapeutic agents remain cisplatin and doxorubicin both hepatoblastoma hepatocellular carcinoma. Unfortunately, these drugs have short long-term toxicities, although a certain extent they can be ameliorated by reducing the cumulative dose changing method administration. This chapter considers improvements supportive care receiving chemotherapy, also discusses late effects therapy. In case cisplatin, kidney ear detected early within 1 2 years ending treatment. After this time, very little or no improvement expected. However, with anthracycline treatment, cardiotoxic are progressive may take 20–30 develop. Long-term follow-up into adult life 5 yearly echocardiographic screening is advised.
springer.com
springerlink.com参考文章(61)
Bernardo Nadal-Ginard, Jan Kajstura, Annarosa Leri, Piero Anversa, Myocyte Death, Growth, and Regeneration in Cardiac Hypertrophy and Failure Circulation Research. ,vol. 92, pp. 139- 150 ,(2003) , 10.1161/01.RES.0000053618.86362.DF
Howard M. Katzenstein, Kay W. Chang, Mark Krailo, Zhengjia Chen, Milton J. Finegold, Jon Rowland, Marleta Reynolds, Alberto Pappo, Wendy B. London, Marcio Malogolowkin, , Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group Cancer. ,vol. 115, pp. 5828- 5835 ,(2009) , 10.1002/CNCR.24667
P.G. Zorowka, H.J. Schmitt, P. Gutjahr, Evoked otoacoustic emissions and pure tone threshold audiometry in patients receiving cisplatinum therapy. International Journal of Pediatric Otorhinolaryngology. ,vol. 25, pp. 73- 80 ,(1993) , 10.1016/0165-5876(93)90011-Q
Elvira C van Dalen, Helena JH van der Pal, Huib N Caron, Leontien CM Kremer, Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy Cochrane Database of Systematic Reviews. ,vol. 2004, ,(2009) , 10.1002/14651858.CD005008.PUB3
Kristin R. Gilmer Knight, Dale F. Kraemer, Edward A. Neuwelt, Ototoxicity in Children Receiving Platinum Chemotherapy: Underestimating a Commonly Occurring Toxicity That May Influence Academic and Social Development Journal of Clinical Oncology. ,vol. 23, pp. 8588- 8596 ,(2005) , 10.1200/JCO.2004.00.5355
Ismo Ilveskoski, Ulla M. Saarinen, Tom Wiklund, Mikko Perkkiö, Toivo T. Salmi, Marjatta Lanning, Anne Mäkipernaa, Helena Pihko, Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol. Medical and Pediatric Oncology. ,vol. 27, pp. 26- 31 ,(1996) , 10.1002/(SICI)1096-911X(199607)27:1<26::AID-MPO6>3.0.CO;2-W
Cameron K. Tebbi, Wendy B. London, Debra Friedman, Doojduen Villaluna, Pedro A. De Alarcon, Louis S. Constine, Nancy Price Mendenhall, Richard Sposto, Allen Chauvenet, Cindy L. Schwartz, Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease Journal of Clinical Oncology. ,vol. 25, pp. 493- 500 ,(2007) , 10.1200/JCO.2005.02.3879
Trijn Israëls, Marianne D. van de Wetering, Peter Hesseling, Nan van Geloven, Huib N. Caron, Elizabeth M. Molyneux, Malnutrition and neutropenia in children treated for burkitt lymphoma in Malawi Pediatric Blood & Cancer. ,vol. 53, pp. 47- 52 ,(2009) , 10.1002/PBC.22032
Gill Levitt, Antoinette Anazodo, Michael Burch, Kathryn Bunch, Cardiac or cardiopulmonary transplantation in childhood cancer survivors: An increasing need? European Journal of Cancer. ,vol. 45, pp. 3027- 3034 ,(2009) , 10.1016/J.EJCA.2009.08.006
Steven E Lipshultz, Stuart R Lipsitz, Endel John Orav, None, Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence. Journal of Clinical Oncology. ,vol. 25, pp. 3179- 3179 ,(2007) , 10.1200/JCO.2007.11.8778